AVITA Medical, Inc. appointed longtime healthcare executive Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. He remains on the Board as an executive director, while Jan Stern Reed has been elected Chair of the Board.
Under a new employment agreement, Mr. Vance receives a base salary of $702,000, an annual bonus target of 80% of salary, and equity awards with cash values of $2,529,000 and $825,000, subject to shareholder approval at the 2027 Annual Meeting. The equity vests over three years in equal annual installments.
If the company terminates him without cause or he resigns for good reason, Mr. Vance is eligible for severance equal to a prorated annual bonus, 18 months of base salary, and 18 months of COBRA premium reimbursement, conditioned on signing a release. The company also confirmed these governance changes in an accompanying press release.
AVITA Medical, Inc. appointed longtime healthcare executive Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. He remains on the Board as an executive director, while Jan Stern Reed has been elected Chair of the Board.
Under a new employment agreement, Mr. Vance receives a base salary of $702,000, an annual bonus target of 80% of salary, and equity awards with cash values of $2,529,000 and $825,000, subject to shareholder approval at the 2027 Annual Meeting. The equity vests over three years in equal annual installments.
If the company terminates him without cause or he resigns for good reason, Mr. Vance is eligible for severance equal to a prorated annual bonus, 18 months of base salary, and 18 months of COBRA premium reimbursement, conditioned on signing a release. The company also confirmed these governance changes in an accompanying press release.
AVITA Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect seven directors, ratify Grant Thornton LLP as auditor for 2026, and increase the non-executive director cash fee pool from US$750,000 to US$900,000.
Stockholders are also asked to approve multiple grants of restricted stock units and options to non-executive directors, advisory votes on executive pay and its frequency, issuance of warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP, and authority to issue additional equity securities up to 10% of issued capital under ASX rules.
AVITA Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect seven directors, ratify Grant Thornton LLP as auditor for 2026, and increase the non-executive director cash fee pool from US$750,000 to US$900,000.
Stockholders are also asked to approve multiple grants of restricted stock units and options to non-executive directors, advisory votes on executive pay and its frequency, issuance of warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP, and authority to issue additional equity securities up to 10% of issued capital under ASX rules.
AVITA Medical, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 3, 2026. The Board set the record date as April 9, 2026, and there were 30,776,689 shares outstanding as of that date. Key items for shareholder votes include election of seven directors; ratification of Grant Thornton LLP as auditor; approval to increase the non-executive director annual cash fee pool from $750,000 to $900,000; multiple grants of restricted stock units and options to non-executive directors (example grants include 22,214 RSUs and 16,133 options to several directors and larger grants to recent appointees); approval to issue warrants covering up to 650,000 shares to Perceptive under a credit agreement; and a special resolution to permit issuance of equity securities up to 10% of issued capital under ASX Listing Rule 7.1A. The proxy materials and the Company’s 2025 Annual Report are available online, and voting instructions are provided for holders of Common Stock and CHESS Depositary Interests (CDIs).
AVITA Medical, Inc. filed a shelf registration statement to offer up to $200,000,000 of common stock, preferred stock, warrants and units under a Form S-3 shelf prospectus dated March 31, 2026. The prospectus states that specific terms for each offering will be set forth in a prospectus supplement. The company's common stock trades on Nasdaq under the symbol RCEL; the prospectus notes a Nasdaq closing price of $3.63 per share as of March 30, 2026. The prospectus says proceeds are expected to be used for general corporate purposes, including capital expenditures and working capital, with precise uses to be specified in future prospectus supplements.
AVITA Medical, Inc. filed a shelf registration statement to offer up to $200,000,000 of common stock, preferred stock, warrants and units under a Form S-3 shelf prospectus dated March 31, 2026. The prospectus states that specific terms for each offering will be set forth in a prospectus supplement. The company's common stock trades on Nasdaq under the symbol RCEL; the prospectus notes a Nasdaq closing price of $3.63 per share as of March 30, 2026. The prospectus says proceeds are expected to be used for general corporate purposes, including capital expenditures and working capital, with precise uses to be specified in future prospectus supplements.
AVITA Medical, Inc. CFO David D. O'Toole increased his stake by buying 1,800 shares of common stock in an open-market purchase at $4.78 per share. After this transaction, he directly owns 141,927 shares, which the disclosure notes include unvested restricted stock units (RSUs).
AVITA Medical, Inc. director Woody Joseph Fralin filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and reports no buy, sell, acquire, or dispose transactions in AVITA Medical, Inc. securities.
AVITA Medical, Inc. director Woody Joseph Fralin filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and reports no buy, sell, acquire, or dispose transactions in AVITA Medical, Inc. securities.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.
AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.
AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of $0.0000 per share and 98,390 shares of Common Stock through restricted stock units.
The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the February 18, 2026 grant date. The stock options vest in three equal annual installments beginning on the first anniversary of the February 18, 2026 grant date, aligning the awards with multi-year service and performance.
AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of $0.0000 per share and 98,390 shares of Common Stock through restricted stock units.
The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the February 18, 2026 grant date. The stock options vest in three equal annual installments beginning on the first anniversary of the February 18, 2026 grant date, aligning the awards with multi-year service and performance.